Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062491 · ClinicalTrials.gov registry record · Phase 2
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
A Phase 2 study of Melanoma and Neoplasm, sponsored by BioNumerik Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT00062491: Completed Phase 2 study of Melanoma and Neoplasm, sponsored by BioNumerik Pharmaceuticals.
NCT00062491 is a Phase 2 study of Melanoma and Neoplasm that has completed, run by BioNumerik Pharmaceuticals. The registered enrollment target is 46 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00062491, a Phase 2 study of Melanoma and Neoplasm, has completed, sponsored by BioNumerik Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.
Interventions
- DRUG Karenitecin (BNP1350)
Study Locations (1)
Florida
- For Information call 210-614-1701 for a site near you - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2002-05 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00062491 record still lists
NCT00062491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Karenitecin (BNP1350) is the first listed.
NCT00062491 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00062491 about?
NCT00062491 is a clinical study titled "Study of Karenitecin (BNP1350) to Treat Malignant Melanoma". The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.
What is the current status of trial NCT00062491?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2002-05. Estimated completion is 2005-11.
What conditions does trial NCT00062491 study?
This clinical trial studies the following conditions: Melanoma, Neoplasm.
What interventions are being tested in trial NCT00062491?
The interventions under investigation include: Karenitecin (BNP1350) (DRUG).
Who is sponsoring clinical trial NCT00062491?
This trial is sponsored by BioNumerik Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00062491 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00062491's enrollment target sits among peer trials
46 171st of 266 higher than 95 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia